Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.

Palma D, Pickles T, Tyldesley S; Prostate Cohort Outcomes Initiative.

BJU Int. 2007 Aug;100(2):315-9.

2.

Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.

King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr.

Urology. 2007 May;69(5):921-6.

PMID:
17482935
4.

Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.

Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG.

J Clin Oncol. 2004 Feb 1;22(3):439-45. Epub 2003 Dec 22.

PMID:
14691120
5.

Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.

Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Zincke H, Blute ML.

Cancer. 2006 Aug 1;107(3):521-9.

6.

Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group.

Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, Terris MK.

J Clin Oncol. 2004 Feb 1;22(3):446-53. Epub 2003 Dec 22.

PMID:
14691122
7.

Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.

Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ.

BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x. Epub 2008 Aug 7.

8.

Body mass index trends and role of obesity in predicting outcome after radical prostatectomy.

Motamedinia P, Korets R, Spencer BA, Benson MC, McKiernan JM.

Urology. 2008 Nov;72(5):1106-10. doi: 10.1016/j.urology.2008.04.021. Epub 2008 Jul 7.

PMID:
18602142
9.

Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy.

van Roermund JG, Hinnen KA, Battermann JJ, Witjes JA, Bosch JL, Kiemeney LA, van Vulpen M.

BJU Int. 2010 Jan;105(1):42-8. doi: 10.1111/j.1464-410X.2009.08687.x. Epub 2009 Jun 10.

10.

Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.

Palma D, Tyldesley S, Blood P, Liu M, Morris J, Pickles T; Prostate Cohort Outcomes Initiative.

Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1425-9.

PMID:
17394943
11.

Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy.

Hisasue S, Yanase M, Shindo T, Iwaki H, Fukuta F, Nishida S, Muranaka T, Miyamoto S, Tsukamoto T, Takatsuka K.

Jpn J Clin Oncol. 2008 Feb;38(2):129-33. doi: 10.1093/jjco/hym162. Epub 2008 Feb 14.

PMID:
18281308
12.

The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.

Kositsawat J, Flanigan RC, Meydani M, Choi YK, Freeman VL.

J Urol. 2007 Dec;178(6):2391-6; discussion 2396. Epub 2007 Oct 22.

PMID:
17936811
13.

Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy.

Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Friedrichs PA, Moul JW.

Urology. 2001 Nov;58(5):723-8.

PMID:
11711349
14.
15.

Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?

Pfitzenmaier J, Pritsch M, Haferkamp A, Jakobi H, Fritsch F, Gilfrich C, Djakovic N, Buse S, Pahernik S, Hohenfellner M.

BJU Int. 2009 Apr;103(7):877-82. doi: 10.1111/j.1464-410X.2008.08149.x. Epub 2008 Oct 24.

16.

Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins.

Freedland SJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Trock B, Aronson WJ; Search Database Study Group.

J Urol. 2004 Aug;172(2):520-4.

PMID:
15247719
17.

Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy.

van Roermund JG, Kok DE, Wildhagen MF, Kiemeney LA, Struik F, Sloot S, van Oort IM, Hulsbergen-van de Kaa CA, van Leenders GJ, Bangma CH, Witjes JA.

BJU Int. 2009 Aug;104(3):321-5. doi: 10.1111/j.1464-410X.2009.08404.x. Epub 2009 Feb 11.

18.

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.

Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T.

J Urol. 2003 May;169(5):1670-5.

PMID:
12686805
19.

The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance.

Ploussard G, de la Taille A, Bayoud Y, Durand X, Terry S, Xylinas E, Allory Y, Vacherot F, Abbou CC, Salomon L.

Eur Urol. 2012 Feb;61(2):356-62. doi: 10.1016/j.eururo.2011.07.041. Epub 2011 Jul 21.

20.

Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.

Briganti A, Karakiewicz PI, Chun FK, Suardi N, Gallina A, Abdollah F, Freschi M, Doglioni C, Rigatti P, Montorsi F.

Int J Urol. 2009 Aug;16(8):676-81. doi: 10.1111/j.1442-2042.2009.02330.x. Epub 2009 Jul 8.

Supplemental Content

Support Center